• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    3/30/23 12:43:14 PM ET
    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANGO alert in real time by email

    Gainers

    • SCYNEXIS, Inc. (NASDAQ:SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront payment of $90 million.
    • Palisade Bio, Inc. (NASDAQ:PALI) rose 49% to $2.51 after Maxim Group upgraded the stock from Hold to Buy and announced a $50 price target.
    • National CineMedia, Inc. (NASDAQ:NCMI) jumped 32.1% to $0.1510. National CineMedia is preparing for Chapter 11 filing, the Wall Street Journal reported last week.
    • Boxed, Inc. (NYSE:BOXD) jumped 31.9% to $0.2120 after declining 6% on Wednesday. Boxed recently said it is evaluating potentially filing for relief under the U.S. Bankruptcy Code and other strategic alternatives.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) surged 27.5% to $0.64 after the company reported better-than-expected Q4 sales results.
    • EVgo, Inc. (NASDAQ:EVGO) shares gained 24.4% to $7.17 after the company reported that fourth-quarter sales nearly quadrupled year-on-year to $27.30 million, beating the consensus of $21.82 million.
    • Toro Corp. (NASDAQ:TORO) climbed 21% to $2.36 after gaining around 20% on Wednesday.
    • Puma Biotechnology, Inc. (NASDAQ:PBYI) gained 20.6% to $3.0750.
    • Safe & Green Holdings Corp. (NASDAQ:SGBX) shares climbed 18.8% to $0.96 after the company reported Q4 results.
    • Conformis, Inc. (NASDAQ:CFMS) jumped 18.5% to $1.79. Conformis recently posted upbeat quarterly results.
    • Digital Media Solutions, Inc. (NYSE:DMS) rose 18.5% to $0.9507. The company recently signed an agreement to acquire the HomeQuote.io home services marketplace from Customer Direct Group, along with their brand direct international ad network.
    • YS Biopharma Co., Ltd. (NASDAQ:YS) gained 17.2% to $2.3797.
    • Eos Energy Enterprises, Inc. (NASDAQ:EOSE) rose 17.1% to $2.46. Eos Energy Enterprises recently reported worse-than-expected Q4 sales results.
    • Adamas One Corp. (NASDAQ:JEWL) gained 15.2% to $0.91.
    • F45 Training Holdings Inc. (NYSE:FXLV) jumped 15% to $1.42.
    • Sprinklr, Inc. (NYSE:CXM) gained 15% to $12.52 after the company reported better-than-expected Q4 EPS and sales results.
    • LightInTheBox Holding Co., Ltd. (NYSE:LITB) climbed 14.5% to $1.66. LightInTheBox named CEO Jian He as Chairman effective March 29 after Zhi Yan resigned due to personal reasons.
    • Fluence Energy, Inc. (NASDAQ:FLNC) gained 13.9% to $18.49. Goldman Sachs upgraded Fluence Energy from Neutral to Buy and raised the price target from $25 to $29.
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) climbed 13.6% to $22.93. Arcturus Therapeutics recently reported better-than-expected Q4 EPS and sales results.
    • NaaS Technology Inc. (NASDAQ:NAAS) gained 13.1% to $8.79.
    • Mullen Automotive, Inc. (NASDAQ:MULN) rose 13.1% to $0.1176 after jumping 11% on Wednesday.
    • Emergent BioSolutions Inc. (NYSE:EBS) gained 11.5% to $10.43 after the FDA approved over-the-counter designation to the company's NARCAN nasal spray.
    • Alpine Acquisition Corporation (NASDAQ:REVE) shares rose 11.2% to $10.56.
    • RenovoRx, Inc. (NASDAQ:RNXT) shares gained 10.7% to $4.3189 after the company announced new data from Phase III clinical trial interim analysis.
    • Better Therapeutics, Inc. (NASDAQ:BTTX) surged 10.6% to $0.7034 after the company reported better-than-expected Q4 EPS results.
    • Cazoo Group Ltd (NYSE:CZOO) shares rose 9.4% to $2.6156 after jumping 15% on Wednesday.
    • Kohl's Corporation (NYSE:KSS) gained 7.2% to $23.65.

    Losers

    • mCloud Technologies Corp. (NASDAQ:MCLD) shares dipped 43% to $0.4101. mCloud announced receipt of Nasdaq notification letter regarding minimum bid price deficiency.
    • Sonida Senior Living, Inc. (NASDAQ:SNDA) fell 33.3% to $7.16 after reporting downbeat Q4 results.
    • AngioDynamics, Inc. (NASDAQ:ANGO) fell 24.3% to $9.38 after the company posted downbeat Q3 results and lowered FY23 outlook.
    • Semtech Corporation (NASDAQ:SMTC) fell 23.1% to $24.71 after posting downbeat Q4 earnings.
    • Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) shares dipped 22.8% to $3.4299 after the company reported worse-than-expected Q4 sales.
    • Blue Star Foods Corp. (NASDAQ:BSFC) fell 22.2% to $0.1220.
    • Cyxtera Technologies, Inc. (NASDAQ:CYXT) dropped 22% to $0.5061. Starboard Value said on March 27, Jeff Smith resigned from board of Cyxtera and representatives of Starboard Value ceased serving as observers on board.
    • Bit Brother Limited (NASDAQ:BTB) fell 20.7% to $1.07.
    • China Automotive Systems, Inc. (NASDAQ:CAAS) dropped 19.9% to $4.8350. China Automotive Systems reported a fourth-quarter FY22 sales decline of 7.2% year-on-year to $128.80 million, missing the consensus of $138.46 million.
    • Laser Photonics Corporation (NASDAQ:LASE) fell 19% to $4.9699 after the company said it will postpone reporting its Q4 ended December 31, 2022.
    • Metropolitan Bank Holding Corp. (NYSE:MCB) fell 18.9% to $28.39.
    • LogicMark, Inc. (NASDAQ:LGMK) shares dropped 17.3% to $0.1610. LogicMark shares jumped over 39% on Wednesday after the company announced financial results for the year ended 2022.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) dipped 16.7% to $2.24.
    • Avidity Biosciences, Inc. (NASDAQ:RNA) dropped 16% to $16.96 as the company issued an update on Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy Type 1.
    • Franklin Covey Co. (NYSE:FC) fell 15.7% to $37.28 after the company reported worse-than-expected Q2 results.
    • Bed Bath & Beyond Inc. (NASDAQ:BBBY) fell 15% to $0.68 after the company entered a $300 million at the market offering program and issued weak Q4 guidance.
    • Codiak BioSciences, Inc. (NASDAQ:CDAK) fell 13.2% to $0.1823 after jumping over 10% on Wednesday. Codiak BioSciences voluntarily filed for protection under Chapter 11 bankruptcy.
    • TORM plc (NASDAQ:TRMD) fell 12.8% to $28.54 after the company reported commencement of a secondary public offering of 5 million of its Class A common shares by a selling shareholder.
    • Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) dropped 9.4% to $6.62.
    • ProQR Therapeutics N.V. (NASDAQ:PRQR) shares fell 7.5% to $2.33. ProQR Therapeutics filed prospectus relates to resale of up to 13.4 million shares by selling shareholders.
    • IHS Holding Limited (NYSE:IHS) fell 6.8% to $8.25. IHS Holding recently reported better-than-expected Q4 sales results.
    • Verint Systems Inc. (NASDAQ:VRNT) dropped 6.6% to $34.99 following Q4 resulst.

    Now Read This: Top 5 Industrials Stocks That Could Lead To Your Biggest Gains In March

    Get the next $ANGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANGO
    $ARCT
    $AXDX
    $BBBY

    CompanyDatePrice TargetRatingAnalyst
    Fluence Energy Inc.
    $FLNC
    2/10/2026$24.00Hold → Buy
    Jefferies
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    1/23/2026$20.00Buy
    Roth Capital
    Kohl's Corporation
    $KSS
    1/14/2026$22.00Hold
    Jefferies
    Sonida Senior Living Inc.
    $SNDA
    1/9/2026Neutral
    Robert W. Baird
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Eos Energy Enterprises Inc.
    $EOSE
    12/17/2025$16.00Neutral
    Analyst
    Phathom Pharmaceuticals Inc.
    $PHAT
    12/12/2025$28.00Strong Buy
    Raymond James
    More analyst ratings

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Read Rory P bought $152 worth of shares (20 units at $7.60) and sold $996,726 worth of shares (165,858 units at $6.01), decreasing direct ownership by 10% to 1,506,270 units (SEC Form 4)

    4 - Sprinklr, Inc. (0001569345) (Issuer)

    2/9/26 5:00:05 PM ET
    $CXM
    Computer Software: Prepackaged Software
    Technology

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Auerbach Alan H was granted 159,778 shares, increasing direct ownership by 2% to 7,305,729 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    2/20/26 8:29:13 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Hunt Douglas M was granted 49,394 shares, increasing direct ownership by 32% to 205,301 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    2/20/26 8:28:40 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Nougues Maximo F was granted 46,739 shares, increasing direct ownership by 24% to 240,023 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    2/20/26 8:28:04 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/11/22 10:17:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026. The Company's presentation will begin at 1:40 p.m. (ET). A live webcast of the event will be accessible through the "Investors" section of the Company's website at www.angiodynamics.com and will be available for replay following the event. About AngioDynamics, Inc. AngioDynamics is a leading

    2/23/26 4:30:00 PM ET
    $ANGO
    Medical/Dental Instruments
    Health Care

    Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutic

    2/23/26 4:15:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bed Bath & Beyond, Inc. Reports Eighth Consecutive Quarter of Measurable Improvement Toward Profitability

    Q4 Reflects Strengthening Revenue Trends, Sustained Margin Expansion and a $118 Million Year-Over-Year Improvement in Operating Cash Flow Use Bed Bath & Beyond, Inc. (NYSE:BBBY), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home and a blockchain asset portfolio, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company delivered its eighth consecutive quarter of measurable improvement toward profitability, reflecting continued margin expansion, disciplined cost management and consistent progress across key operating metrics. The Company has successfully built the base of its business through disciplined retail executio

    2/23/26 4:01:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    SEC Filings

    View All

    SEC Form 8-K filed by Sonida Senior Living Inc.

    8-K - SONIDA SENIOR LIVING, INC. (0001043000) (Filer)

    2/23/26 5:26:57 PM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    SEC Form 425 filed by Bed Bath & Beyond Inc.

    425 - BED BATH & BEYOND, INC. (0001130713) (Filed by)

    2/23/26 5:11:53 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form DEF 14C filed by Blue Star Foods Corp.

    DEF 14C - Blue Star Foods Corp. (0001730773) (Filer)

    2/23/26 4:51:03 PM ET
    $BSFC

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fluence upgraded by Jefferies with a new price target

    Jefferies upgraded Fluence from Hold to Buy and set a new price target of $24.00

    2/10/26 7:57:53 AM ET
    $FLNC
    Industrial Machinery/Components
    Miscellaneous

    Roth Capital initiated coverage on Arcturus Therapeutics with a new price target

    Roth Capital initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $20.00

    1/23/26 8:16:17 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Kohl's with a new price target

    Jefferies resumed coverage of Kohl's with a rating of Hold and set a new price target of $22.00

    1/14/26 8:43:49 AM ET
    $KSS
    Department/Specialty Retail Stores
    Consumer Discretionary

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Financials

    Live finance-specific insights

    View All

    Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutic

    2/23/26 4:15:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bed Bath & Beyond, Inc. Reports Eighth Consecutive Quarter of Measurable Improvement Toward Profitability

    Q4 Reflects Strengthening Revenue Trends, Sustained Margin Expansion and a $118 Million Year-Over-Year Improvement in Operating Cash Flow Use Bed Bath & Beyond, Inc. (NYSE:BBBY), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home and a blockchain asset portfolio, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company delivered its eighth consecutive quarter of measurable improvement toward profitability, reflecting continued margin expansion, disciplined cost management and consistent progress across key operating metrics. The Company has successfully built the base of its business through disciplined retail executio

    2/23/26 4:01:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    EVgo to Report Fourth Quarter and Full Year 2025 Results on March 3

    LOS ANGELES, Feb. 20, 2026 (GLOBE NEWSWIRE) -- EVgo Inc. (NASDAQ:EVGO), one of the nation's largest providers of public fast charging infrastructure for electric vehicles (EVs), today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, March 3. This release will be followed by a webcast hosted by members of the EVgo management team at 8 a.m. ET (5 a.m. PT). EVgo Fourth Quarter and Full Year 2025 WebcastWhen: Tuesday, March 3Time: 8 a.m. ET (5 a.m. PT)Live Webcast: https://investors.evgo.com/events-and-presentations A copy of the press release with the financial results and the presentation discussed during the webcast will be available on th

    2/20/26 7:00:00 AM ET
    $EVGO
    EDP Services
    Technology

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eos Energy Enterprises Inc.

    SC 13D/A - Eos Energy Enterprises, Inc. (0001805077) (Subject)

    12/17/24 2:48:02 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    ProQR Announces Planned Changes to Board Composition

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni

    2/9/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care